Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR2 S252W |
Therapy | Dovitinib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | conflicting |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 S252W | Advanced Solid Tumor | conflicting | Dovitinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing FGFR2 S252W were sensitive to Dovitinib (TKI258) (PMID: 23908597). | 23908597 |
FGFR2 S252W | Advanced Solid Tumor | conflicting | Dovitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 S252W were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467). | 34272467 |
PubMed Id | Reference Title | Details |
---|---|---|
(23908597) | The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. | Full reference... |
(34272467) | Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer. | Full reference... |